Erythema Multiforme and COVID-19: What Do We Know?

Luigi Bennardo, Steven Paul Nisticò, Stefano Dastoli, Eugenio Provenzano, Maddalena Napolitano, Martina Silvestri, Maria Passante, Cataldo Patruno

Medicina (Kaunas, Lithuania) 2021 Aug 16

filter terms:

Background: Erythema multiforme (EM) is an acute cutaneous eruption often associated with infections and more rarely with drugs. This review aimed to evaluate the association between erythema multiforme and coronavirus disease 2019 (COVID-19). Methods: A systematic search of PubMed/MEDLINE, Scimago Scopus, and ISI/Web of Science was performed. Original articles, case series, or case reports were evaluated and selected. Results: Fourteen articles were selected, describing a total of 70 patients. EM is a cutaneous eruption rarely occurring in COVID-19 and is, in most cases, associated with a hypersensitivity reaction to the virus. In these cases, EM seems to affect patients younger than 30 years or older than 55 years. Infrequently, some drugs used in the management of COVID-19 may induce EM, especially hydroxychloroquine. The three groups of patients seem to have different clinical characteristics and courses. Conclusions: From these data, it is possible to preliminarily propose that EM or EM-like eruptions linked to COVID-19 might be divided into three types: the virus-related juvenile type (affecting patients <30-year-old), the virus-related older type (affecting patients >55 years), and the drug-induced type. The occurrence of a skin rash does not seem to be related to the severity and clinical course of COVID-19.

Citation

Luigi Bennardo, Steven Paul Nisticò, Stefano Dastoli, Eugenio Provenzano, Maddalena Napolitano, Martina Silvestri, Maria Passante, Cataldo Patruno. Erythema Multiforme and COVID-19: What Do We Know? Medicina (Kaunas, Lithuania). 2021 Aug 16;57(8)